This Week: and lots more… Earlier this month, Matthias Liechti and Felix Mueller shared preliminary results from their Phase 2 LSD for major depressive disorder (MDD) trial.The topline findings report “significant, rapid, durable and beneficial effects” of LSDAccording to MindMed’s press release: As a reminder, MindMed collaborates with the Liechti Lab at University Hospital Basel…


Previous articlePsychedelics Weekly – Breaking Convention, Decolonizing the Psychedelic Space, and How Colorado’s Senate Bill 23-290 Will Affect Prop 122
Next articleRevive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19